Winton Group’s Mirum Pharmaceuticals MIRM Stock Holding History

Winton Group’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,191	Closed	-$202K	–	1373
2026 Q1	$202K	Buy	+2,191	New	+$206K	0.01%	975

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's MIRM Position: Q2 2026 in Review

Winton Group sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 2,191 shares — an estimated $202K sold.

Winton Group first reported a position in MIRM in Q1 2026 and held it in 1 quarter. The position peaked at $202K in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Winton Group reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Winton Group sold 2,191 Mirum Pharmaceuticals shares in Q2 2026, an estimated $202K.
Winton Group first reported a position in Mirum Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Winton Group's Mirum Pharmaceuticals position peaked at $202K in Q1 2026.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.